Co-Diagnostics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.87M
- P/E (TTM)
- –
- Dividend yield
- –
About Co-Diagnostics
Surgical & Medical Instruments & Apparatus, SIC 3841
Co-Diagnostics, Inc. develops, manufactures, and sells molecular diagnostics reagents and testing systems that detect and analyze nucleic acid molecules. The company utilizes its proprietary Co-Primers polymerase chain reaction technology to produce diagnostic tests for infectious diseases, including COVID-19, influenza, tuberculosis, hepatitis, human papillomavirus, malaria, dengue, and Zika. In addition to human medical tests, it provides solutions for identifying genetic traits in plant and animal genomes as well as mosquito surveillance tests. It also develops the portable Co-Dx PCR platform comprising testing instruments, test cups, and mobile software. Its offerings serve clinical laboratories, research partners, and municipal organizations.
The company is headquartered in Salt Lake City, Utah. Its operations and commercial reach include a global distribution network supplying clinical laboratories across more than fifty countries. Furthermore, it operates through a manufacturing and development joint venture in India and maintains regulatory clearances for its diagnostic tests in markets including the United States, the European Community, the United Kingdom, Australia, Mexico, and India.
Summary of the business section of Co-Diagnostics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Co-Diagnostics, Inc.
- Headquarters
- Salt Lake City, UT
- Address
- 2401 S Foothill Drive, Suite D 84109
- Phone
- (801) 438-1036
- Website
- codiagnostics.com
- Employees
- 115, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Utah
- Fiscal year ends
- December 31
- Auditor
- Tanner LLP, Salt Lake City, Utah
Stock & identifiers
- Ticker
- CODX
- Exchange
- Nasdaq
- IPO date
- Jul 13, 2017
- Shares outstanding
- 6M, Aug 11, 2026
- Public float
- $10.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Mar 31, 2026; 1-for-30 reverse, Jan 2, 2026
- SEC CIK
- 1692415
- CUSIP
- 189763204
- ISIN
- US1897632048
- LEI
- 549300Z1JPESYWFM1R93
- EIN
- 46-2609396
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dwight H. Egan | Chief Executive Officer, Director | 29,526 |
| Daniel Bohrer | EVP of Finance & Accounting | 3,657 |
| Richard David Abbott | President | 594,233 |
| Brian Lee Brown | Chief Financial Officer | 23,729 |
| James B. Nelson | Director | 10,668 |
| Eugene Durenard | Director | 10,668 |
| Richard S. Serbin | Director | 10,751 |
| Edward L. Murphy | Director | 11,084 |
| Ted Murphy | Director | 224,167 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dwight Egan | $528.75K | $276.45K | $390.63K | $13 | – |
| FY2024 Dwight Egan | $716.92K | $421.35K | $501.48K | $56 | – |
| FY2023 Dwight Egan | $1.26M | $579.60K | $1.03M | $15 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 115 full-time and part-time employees at our executive offices and lab facilities in Salt Lake City, Utah.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 13, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 10, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 5, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 5, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 1, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 13, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 11, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |